HMGB1 and breast cancer: Likewise, HMGB1/TLR4/NF-κB signaling mediates metastasis and enhances inflammatory cytokine production in breast cancer [204], while drug-resistant myeloma cells exhibit increased HMGB1 release, whereby silencing HMGB1 diminishes NF-κB phosphorylation and restores drug sensitivity [207].